141 Participants Needed

A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)

(INDUS-3 Trial)

Recruiting at 24 trial locations
SP
DM
RR
Overseen ByRavitej Ramachandran, MSc
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Aurigene Discovery Technologies Limited
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This trial is testing AUR101, a new medication, in patients with moderate-to-severe plaque psoriasis. The goal is to see if AUR101 can reduce symptoms by targeting inflammation and slowing down skin cell growth.

Will I have to stop taking my current medications?

Yes, you will need to stop taking certain medications before joining the trial. Specifically, you must stop using biological agents for psoriasis 3 to 6 months before, non-biological systemic medications 4 weeks before, and medicated topical agents 2 weeks before the study starts.

What safety data exists for the treatment evaluated under names like AUR101 and others?

The safety data for treatments like AUR101 is often derived from randomized controlled trials, which compare the treatment to a placebo (a dummy treatment with no active ingredients). These trials help identify adverse events (unwanted side effects) and their frequency, but reporting on safety is often less detailed than on effectiveness. It's important to look at drug labels and databases like SIDER for detailed side effect information.12345

Research Team

DM

Divyesh Mandavia, MD

Principal Investigator

Aurigene Discovery Technologies Limited

Eligibility Criteria

Inclusion Criteria

You are able to communicate well with the investigator and to comply with the requirements of the entire study.
Psoriasis of at least moderate severity, defined as PASI≥12 and involved BSA≥10 % at screening and Day 1
You have chronic plaque-type psoriasis, diagnosed at least 6 months before screening.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive AUR101 or placebo in a double-blind, double-dummy manner for 16 weeks

16 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks

Treatment Details

Interventions

  • AUR101
  • Placebo
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: AUR101 400 mg PO QDExperimental Treatment1 Intervention
Patients will receive AUR101 / placebo in double blind, double dummy manner
Group II: AUR101 400 mg PO BIDExperimental Treatment1 Intervention
Patients will receive AUR101 / placebo in double blind, double dummy manner
Group III: AUR101 200 mg PO BIDExperimental Treatment1 Intervention
Patients will receive AUR101 / placebo in double blind, double dummy manner
Group IV: PlaceboPlacebo Group1 Intervention
Patients will receive AUR101 / placebo in double blind, double dummy manner

Find a Clinic Near You

Who Is Running the Clinical Trial?

Aurigene Discovery Technologies Limited

Lead Sponsor

Trials
10
Recruited
640+

Findings from Research

The study analyzed adverse event (AE) data from six randomized controlled trials involving schizophrenia treatments, highlighting that the absolute prevalence and expected duration of AEs provide a more comprehensive understanding of a drug's safety compared to just incidence rates.
Using a new metric to assess the drug-placebo difference in AE prevalence, the research found that some AEs not listed in the standard drug label significantly impacted drug tolerability, suggesting that including these metrics in drug labels could enhance safety signal detection and inform better treatment choices.
A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels.Piacentino, D., Ogirala, A., Lew, R., et al.[2023]
A review of 192 randomized clinical trials revealed that safety information is often underreported, with only 46% specifying reasons for withdrawals due to toxicity and only 39% adequately reporting clinical adverse effects.
To enhance safety reporting, the study emphasizes the need for standardized scales for adverse effects, systematic data collection, and detailed reporting of severe reactions, suggesting that improved practices could lead to better safety insights in clinical trials.
Improving safety reporting from randomised trials.Ioannidis, JP., Lau, J.[2018]
The review of clinical research data from 1977 to 2011 highlights significant inconsistencies in how adverse reactions (AR) to drugs are assessed, which can affect the reliability of safety information provided to patients.
To improve the safety profiles of medications, the authors advocate for the establishment of a common European standard for the structured assessment of adverse reactions in clinical research, as no such standard currently exists.
[Assessing adverse reactions in clinical trials].Harnisch, S., Schade-Brittinger, C., Rief, W.[2013]

References

A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels. [2023]
Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical Trials. [2020]
The SIDER database of drugs and side effects. [2022]
Improving safety reporting from randomised trials. [2018]
[Assessing adverse reactions in clinical trials]. [2013]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security